Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661764 · ClinicalTrials.gov registry record · Phase 2
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention
A Phase 2 study of Colorectal Adenomatous Polyps, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 2
- Development phase
- 141
- Enrollment target
- 1
- Study location
NCT01661764 is a Phase 2 study of Colorectal Adenomatous Polyps that has completed, run by Vanderbilt University. The registered enrollment target is 141 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01661764, a Phase 2 study of Colorectal Adenomatous Polyps, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 141 participants
- Enrollment target
- 1
- Study location
Study Summary
Colorectal cancer is the second leading cause of cancer-related death within the United States. Animal models and observational studies have suggested that marine-derived n-3 polyunsaturated fatty acids \[PUFA\] such as eicosapentanoic acid \[EPA\] and docosahexanoic acid \[DHA\] may reduce the risk of colorectal cancer. In addition, it may be the relative proportion of n-3 to n-6 PUFAs that best determines the chemopreventive effects of fish oils. This ratio is important because the n-6 PUFA, arachidonic acid (ARA), is converted via the cyclo-oxygenase (COX) pathway to prostaglandin E2 (PGE2), an inflammatory eicosanoid overproduced in colorectal neoplasms while EPA is converted to the anti-inflammatory prostaglandin E3 (PGE3). While the ratio of n-6 to n-3 PUFAs can be altered through dietary changes, genetic factors may also influence this ratio. Recent genetic studies have demonstrated that much of the tissue levels of ARA is determined by differences in a gene called fatty acid desaturase 1 (FADS1). FADS1 is the rate-limiting enzyme in the conversion of linoleic acid, the most commonly consumed PUFA in the Western diet, to ARA, and one particular genetic variant caller rs174537 is associated with lower fatty acid desaturase activity and subsequently lower tissue levels of ARA. The study hypothesis is that individuals with genetically determined lower activity of FADS1 will derive greater benefit from fish oil supplementation than individuals with higher FADS1 activity because of lower tissue levels of ARA and subsequently a more favorable n-6 to n-3 PUFA ratio. To test this hypothesis the investigators will recruit 150 participants with recently identified adenomatous polyps and conduct a 6-month double blind 3 X 2 factorial randomized controlled trial. The first factor will be FADS1 genotype (GG, GT, and TT) and the second factor will be fish oil supplementation (fish oil versus placebo). The primary outcome will be the change in rectal epithelial cell growth
Conditions Studied
Interventions
- DRUG Eicosapentanoic acid and docosahexanoic acid
- DRUG Oleic Acid
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2013-02-04 |
| Est. Completion | 2018-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01661764
The ClinicalTrials.gov registry entry for NCT01661764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Adenomatous Polyps appearing as the primary indexed condition, and to 2 interventions - of which Eicosapentanoic acid and docosahexanoic acid is the first listed.
NCT01661764 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT01661764 about?
NCT01661764 is a clinical study titled "Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention". Colorectal cancer is the second leading cause of cancer-related death within the United States. Animal models and observational studies have suggested that marine-derived n-3 polyunsaturated fatty acids \[PUFA\] such as eicosapentanoic acid \[EPA\] and docosahexanoic acid \[DHA\] may reduce the risk...
What is the current status of trial NCT01661764?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 141 participants. The study started on 2013-02-04. Estimated completion is 2018-01-23.
What conditions does trial NCT01661764 study?
This clinical trial studies the following conditions: Colorectal Adenomatous Polyps.
What interventions are being tested in trial NCT01661764?
The interventions under investigation include: Eicosapentanoic acid and docosahexanoic acid (DRUG), Oleic Acid (DRUG).
Who is sponsoring clinical trial NCT01661764?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01661764 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Adenomatous Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.